Accede al análisis completo con tu suscripción
Últimos 20 reportes · 10-K · 10-K/A · 10-Q · 8-K · Fuente: SEC EDGAR
Accede al análisis completo con tu suscripción
SEC CIK: 0001944048
At Kenvue, our purpose is to realize the extraordinary power of everyday care. As a global leader at the intersection of healthcare and consumer goods, we are the world’s largest pure-play consumer health company by revenue with $15.1 billion in Net sales in the fiscal year 2025. By combining the power of science with meaningful consumer insights and our digital strategy, we empower consumers to live healthier lives every day. Built on more than a century of heritage and trusted by generations, our differentiated portfolio of iconic brands—including Aveeno ® , BAND-AID ® Brand, Johnson’s ® , Listerine ® , Neutrogena ® , Nicorette ® , Tylenol ® , and Zyrtec ® —is backed by science and recommended by healthcare professionals, which further reinforces our consumers’ connections to our brands. Our portfolio includes Self Care, Skin Health and Beauty, and Essential Health products, allowing us to connect with consumers across North America, Asia Pacific (“APAC”), Europe, Middle East, and Africa (“EMEA”), and Latin America (“LATAM”) in their daily rituals and the moments that matter most. Our products are marketed across more than 165 countries worldwide.
Ver másPrecio actual · USD
$18.01
Consenso de Analistas
Precio Objetivo — 12 meses
$18.00
Mínimo
-0.1%
$19.00
Mediana
+5.5%
$19.50
Promedio
+8.3%
$23.00
Máximo
+27.7%
P/E LTM
20.70
ROIC (NOPAT / capital invertido)
10.9%
Margen Neto (continuadas)
10.8%
P/FCF
18.09x
Current Ratio
1.01x
Debt / Equity Ratio
0.80x
Gross Margin
58.2%
Margen operativo
17.1%
| Métrica | LTM jun 26 | 2025 | 2024 | 2023 | 🔒Premium | 🔒Premium |
|---|---|---|---|---|---|---|
| INGRESOS Y MÁRGENES | ||||||
| Ingresos Totales | 15.408B | 15.124B | 15.455B | 15.444B | 🔒 | 🔒 |
| Coste de Ventas | 6.442B | 6.332B | 6.496B | 6.801B | 🔒 | 🔒 |
| Beneficio Bruto | 8.966B | 8.792B | 8.959B | 8.643B | 🔒 | 🔒 |
| GASTOS OPERATIVOS | ||||||
| I+D | 370.000M | 382.000M | 408.000M | 399.000M | 🔒 | 🔒 |
| SG&A | 6.037B | 6.088B | 6.329B | 6.141B | 🔒 | 🔒 |
| Publicidad y marketing | — | |||||
| RESULTADO OPERATIVO | ||||||
| Resultado operativo | 2.630B | 2.414B | 1.841B | 2.512B | 🔒 | 🔒 |
| EBIT | 2.630B | 2.414B | 1.841B | 2.512B | 🔒 | 🔒 |
| EBITDA | 3.197B | 2.971B | ||||
| RESULTADO NETO | ||||||
| Resultado antes de impuestos | 2.223B | 1.999B | 1.415B | 2.190B | 🔒 | 🔒 |
| Gastos por intereses | 425.000M | 430.000M | 431.000M | 358.000M | 🔒 | 🔒 |
| Impuesto sobre beneficios | 565.000M | 529.000M | 385.000M | |||
| CAPITAL CIRCULANTE | ||||||
| Existencias | 1.722B | 1.666B | 1.591B | 1.851B | 🔒 | 🔒 |
| Clientes | 2.476B | 2.382B | 2.165B | 2.073B | 🔒 | 🔒 |
| Proveedores | 2.577B | 2.473B | 2.254B | 2.489B | ||
| LIQUIDEZ | ||||||
| Efectivo y equivalentes | 1.110B | 1.062B | 1.070B | 1.382B | 🔒 | 🔒 |
| Liquidez Total | 1.110B | 1.062B | 1.070B | 1.382B | 🔒 | 🔒 |
| BALANCE — ACTIVOS | ||||||
| Inmovilizado material (neto) | 2.226B | 2.212B | 1.849B | 2.042B | 🔒 | 🔒 |
| Fondo de comercio | 9.265B | 9.509B | 8.843B | 9.271B | 🔒 | 🔒 |
| Intangibles | 8.406B | 8.694B | 8.474B | 9.619B | 🔒 | |
| CAPITAL Y DEUDA | ||||||
| Deuda a largo plazo | 7.074B | 7.071B | 7.055B | 7.687B | 🔒 | 🔒 |
| Deuda a corto plazo | 1.406B | 1.453B | 1.552B | 599.000M | 🔒 | 🔒 |
| Deuda Total | 8.480B | 8.524B | 8.607B | 8.286B | ||
| FLUJO DE CAJA Y RETRIBUCIÓN AL ACCIONISTA | ||||||
| Flujo de Caja Operativo | 2.325B | 2.197B | 1.769B | 3.168B | 🔒 | 🔒 |
| Capex | 411.000M | 475.000M | 434.000M | 469.000M | 🔒 | 🔒 |
| Free Cash Flow | ||||||
| RATIOS | ||||||
| ROIC (NOPAT / capital invertido) | 10.9% | 9.7% | 7.8% | |||
Cifras en miles de millones (B) · Fuente: SEC/EDGAR
| 1.836B |
| 1.869B |
| 1.577B |
| 🔒 |
| 🔒 |
| Deterioro de activos | 23.000M | 23.000M | 578.000M | 0.00 | 🔒 | 🔒 |
| Amortización de intangibles | 259.000M | 257.000M | 269.000M | 322.000M | 🔒 | 🔒 |
| Reestructuración | 300.000M | 290.000M | 185.000M | 0.00 | 🔒 | 🔒 |
| Depreciación y Amortización | 567.000M | 557.000M | 622.000M | 627.000M | 🔒 | 🔒 |
| Stock-Based Compensation | 116.000M | 136.000M | 254.000M | 188.000M | 🔒 | 🔒 |
| 2.463B |
| 3.139B |
| 🔒 |
| 🔒 |
| NOPAT (numerador del ROIC) | 1.962B | 1.775B | 1.340B | 1.909B | 🔒 | 🔒 |
| 526.000M |
| 🔒 |
| 🔒 |
| Beneficio Neto | 1.658B | 1.470B | 1.030B | 1.664B | 🔒 | 🔒 |
| BPA Diluido | 0.87 | 0.76 | 0.54 | 0.90 | 🔒 | 🔒 |
| BPA Básico | 0.87 | 0.77 | 0.54 | 0.90 | 🔒 | 🔒 |
| 🔒 |
| 🔒 |
| Activo Corriente | 5.899B | 5.697B | 5.525B | 6.138B | 🔒 | 🔒 |
| Pasivo Corriente | 5.867B | 5.945B | 5.739B | 5.481B | 🔒 | 🔒 |
| Capital Circulante | 32.000M | -248.000M | -214.000M | 657.000M | 🔒 | 🔒 |
| 🔒 |
| Activo Total | 26.735B | 27.076B | 25.601B | 27.851B | 🔒 | 🔒 |
| Pasivo Total | 16.182B | 16.311B | 15.933B | 16.640B | 🔒 | 🔒 |
| Pasivo por arrendamiento operativo | 133.000M | 150.000M | 112.000M | 141.000M | 🔒 | 🔒 |
| Pasivo por arrendamiento financiero | — | 135.000M | 121.000M | — | 🔒 | 🔒 |
| 🔒 |
| Deuda Neta | 7.370B | 7.462B | 7.537B | 6.904B | 🔒 | 🔒 |
| Patrimonio Neto | 10.553B | 10.765B | 9.668B | 11.211B | 🔒 | 🔒 |
| Capital Invertido | 17.923B | 18.227B | 17.205B | 18.115B | 🔒 | 🔒 |
| Acciones en Circulación | 1.920B | 1.916B | 1.914B | 1.915B | 🔒 | 🔒 |
| Acciones diluidas (media del periodo) | 1.922B | 1.924B | 1.923B | 1.850B | 🔒 | 🔒 |
| 1.914B |
| 1.722B |
| 1.335B |
| 2.699B |
| 🔒 |
| 🔒 |
| FCF por acción | 1.00 | 0.90 | 0.69 | 1.46 | 🔒 | 🔒 |
| Dividendos pagados | 1.592B | 1.581B | 1.552B | 766.000M | 🔒 | 🔒 |
| Dividendo por acción | 0.83 | 0.82 | 0.81 | 0.40 | 🔒 | 🔒 |
| Recompras de acciones | 70.000M | 197.000M | 235.000M | 7.000M | 🔒 | 🔒 |
| 10.5% |
| 🔒 |
| 🔒 |
| Margen Neto (continuadas) | 10.8% | 9.7% | 6.7% | 10.8% | 🔒 | 🔒 |
| Current Ratio | 1.01x | 0.96x | 0.96x | 1.12x | 🔒 | 🔒 |
| Debt / Equity Ratio | 0.80x | 0.79x | 0.89x | 0.74x | 🔒 | 🔒 |
| Gross Margin | 58.2% | 58.1% | 58.0% | 56.0% | 🔒 | 🔒 |
| Margen operativo | 17.1% | 16.0% | 11.9% | 16.3% | 🔒 | 🔒 |
| Publicidad / Ingresos | — | 12.1% | 12.1% | 10.2% | 🔒 | 🔒 |
| Margen EBIT | 17.1% | 16.0% | 11.9% | 16.3% | 🔒 | 🔒 |
| EBITDA Margin | 20.8% | 19.6% | 15.9% | 20.3% | 🔒 | 🔒 |
| FCF Margin | 12.4% | 11.4% | 8.6% | 17.5% | 🔒 | 🔒 |
| Crecimiento Ingresos | 1.8% | -2.1% | 0.1% | 3.3% | 🔒 | 🔒 |
| SG&A / Ingresos | 39.2% | 40.3% | 41.0% | 39.8% | 🔒 | 🔒 |
| I+D / Ingresos | 2.4% | 2.5% | 2.6% | 2.6% | 🔒 | 🔒 |
| Amort. intangibles / Ingresos | 1.7% | 1.7% | 1.7% | 2.1% | 🔒 | 🔒 |
| SBC / Ingresos | 0.8% | 0.9% | 1.6% | 1.2% | 🔒 | 🔒 |
| Capex / Ingresos | 2.7% | 3.1% | 2.8% | 3.0% | 🔒 | 🔒 |
| Existencias / Ingresos | 11.2% | 11.0% | 10.3% | 12.0% | 🔒 | 🔒 |
| ROE (beneficio total) | 15.6% | 14.4% | 9.9% | 10.7% | 🔒 | 🔒 |
| ROA (beneficio total) | 6.2% | 5.6% | 3.9% | 6.0% | 🔒 | 🔒 |
| Effective Tax Rate | 25.4% | 26.5% | 27.2% | 24.0% | 🔒 | 🔒 |
| Quick Ratio | 0.61x | 0.58x | 0.56x | 0.63x | 🔒 | 🔒 |
| Net Debt / EBITDA | 2.31x | 2.51x | 3.06x | 2.20x | 🔒 | 🔒 |
| Interest Coverage | 6.19x | 5.61x | 4.27x | 7.02x | 🔒 | 🔒 |
| Coste medio de la deuda | 5.0% | 5.0% | 5.0% | 4.3% | 🔒 | 🔒 |
| Deuda / Total Activos | 31.7% | 31.5% | 33.6% | 29.8% | 🔒 | 🔒 |
| Fondo de comercio + intangibles / Activo | 66.1% | 67.2% | 67.6% | 67.8% | 🔒 | 🔒 |
| Días de inventario | 97.6 d | 96.0 d | 89.4 d | 99.3 d | 🔒 | 🔒 |
| Días de cobro (DSO) | 58.7 d | 57.5 d | 51.1 d | 49.0 d | 🔒 | 🔒 |
| Días de pago (DPO) | 146.0 d | 142.6 d | 126.6 d | 133.6 d | 🔒 | 🔒 |
| Ciclo de conversión de caja | 10.3 d | 10.9 d | 13.9 d | 14.7 d | 🔒 | 🔒 |
| Payout (BPA con discont.) | 95.4% | 107.9% | 150.0% | 44.4% | 🔒 | 🔒 |
| Payout sobre FCF | 83.2% | 91.8% | 116.3% | 28.4% | 🔒 | 🔒 |
| Retorno al accionista / FCF | 86.8% | 103.3% | 133.9% | 28.6% | 🔒 | 🔒 |